Bloomberg Television
@markets·3.2M subscribers·95.6K videos
Novo Nordisk CSO on New Obesity Shot Results and Drug Pipeline
Posted
February 23, 2026
Views
25,416
Likes
88
Comments
57
Engagement
February 23, 2026
25,416
88
57
0.57%
Every word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
4:46Now PlayingNovo Nordisk Chief Scientific Officer Martin Holst Lange discusses the recent clinical trial results of the company's weight loss obesity shot CagriSema, which delivered less weight loss than Eli Lilly’s tirzepatide. Holst Lange also outlines Novo Nordisk's broader obesity treatment pipeline. He speaks on "Bloomberg Open Interest."
--------
More on Bloomberg Television and Markets
Like this video? Subscribe and turn on notifications so you don't miss any videos from Bloomberg Markets & Finance
Visit for business news & analysis, uptotheminute market data, features, profiles and more.
Connect with Bloomberg Television on:
Connect with Bloomberg Business on:
More from Bloomberg:
Bloomberg Radio
Bloomberg Surveillance
Bloomberg Politics
Bloomberg Originals
Watch more on YouTube:
Bloomberg Technology
Bloomberg Originals
Bloomberg Quicktake
Bloomberg Espanol
Bloomberg Podcasts
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.
